Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 HKD | 0.00% | 0.00% | -16.67% |
04-01 | PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9% | MT |
03-28 | PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2021 | 660M 84.26M 6.75B | Sales 2022 | 448M 57.24M 4.58B | Capitalization | 506M 64.6M 5.17B |
---|---|---|---|---|---|
Net income 2021 | -122M -15.58M -1.25B | Net income 2022 | -120M -15.33M -1.23B | EV / Sales 2021 | 1.14 x |
Net Debt 2021 | 436M 55.68M 4.46B | Net Debt 2022 | 427M 54.59M 4.37B | EV / Sales 2022 | 2.08 x |
P/E ratio 2021 |
-2.62
x | P/E ratio 2022 |
-4.2
x | Employees | 662 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.06% |
Current month | -9.64% | ||
1 month | -7.41% | ||
3 months | -7.41% | ||
6 months | -25.74% | ||
Current year | -16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Yu Ling Chan
CEO | Chief Executive Officer | 63 | 04/05/98 |
Hang Woon Ma
SAM | Sales & Marketing | - | - |
Pui Hung
HRO | Human Resources Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Kwok Wah Ho
BRD | Director/Board Member | 65 | 11/06/15 |
Lim Kin Leung
BRD | Director/Board Member | 70 | 11/06/15 |
Yu Ling Chan
CEO | Chief Executive Officer | 63 | 04/05/98 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.75 | 0.00% | 70,000 |
25/04/24 | 0.75 | 0.00% | 0 |
24/04/24 | 0.75 | +1.35% | 208,000 |
23/04/24 | 0.74 | -1.33% | 83,500 |
22/04/24 | 0.75 | 0.00% | 136,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.67% | 37.85M | |
+35.04% | 5.92B | |
-15.13% | 4.51B | |
-9.75% | 3.15B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
-7.89% | 1.68B | |
+0.09% | 1.65B | |
-12.97% | 1.53B |
- Stock Market
- Equities
- 1498 Stock